A generic version of Crestor®, launched before patents expire.
TORONTO, April 2, 2012 /CNW/ - Apotex Inc. the largest Canadian owned
pharmaceutical company, launched today Apo-Rosuvastatin, a generic
version of Crestor® produced by AstraZeneca. The Apotex product is 100% Canadian made by
employees and facilities dedicated to ensuring that Canada remains a
global strength in generic product introduction. With annual Crestor® brand sales in Canada of over $700 million, generic Rosuvastatin
represents the second largest generic product launch in this market to
date. The launch of Apo-Rosuvastatin comes years before the last
Crestor® patents are set to expire, in August 2020. To the Canadian healthcare
system, the availability a generic rosuvastatin up to 8 years early
could represent up to $3.4 billion in accumulative savings.
"We are pleased that our efforts in litigation have delivered yet
another blockbuster to the Canadian generic market. Apotex continues
to lead the way in launching generic products sooner, enabling more
affordable healthcare for Canadians" stated Jack Kay, Apotex CEO. "We
are especially proud that everything from research and development
through to manufacturing of Apo-Rosuvastatin is done right here in
Apotex has over 6,000 employees in 21 facilities, producing 300
pharmaceuticals that are exported to 115 countries. It is the top
pharmaceutical Research and Development company in Canada with planned
expenditures of $2 billion over the next ten years. Apotex is also the only significant Canadian producer of active
pharmaceutical chemicals and the only company that produces the
Rosuvastatin raw material in Canada.
*IMS Canada 2011
®Trademarks are owned by their respective owners.
SOURCE Apotex Inc.
For further information:
Director, Public & Government Affairs
Tel: 416-749-9300, ext. 7366
Fax: (416) 401-3835